Figure 8. HER2 expression on immunostaining and HER2 accessibility on 89Zr-Trastuzumab PET are not concordant in regards to their association with MUC4 or metabolic change on 18F-FDG.
The side by side comparison of the association of HER2 expression levels ( left) and 89Zr-Trastuzumab uptake (right) with (A) MUC4 is shown including both JIMT1 (HER2+/MUC4+) and SKBr3 (HER2+/MUC4-) tumors in dual-tumor-bearing mice randomized to the four treatment arms CS (Control+Saline), CT (Control+Trastuzumab), NS (NAC+Saline) and NT (NAC+Trastuzumab). (B) The side by side comparison of the association to 18F-FDG PET metabolic response is limited to mice randomized to the trastuzumab treatment arms CT and NT are also represented. Data shown include both tumor types and are expressed in IM scores for HER2 and MUC4 expression, in SUVmax for 89Zr-Trastuzumab uptake and expressed as the percentage difference in SUVmax (%ΔSUVmax) for 18F-FDG metabolic response.